AbsEn.i
Curation
Istex
Racine
Curation
Checkpoint
Istex
Racine
Istex
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Curation (Istex)

Index « AbsEn.i » - entrée « suggest »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
sufficiently < suggest < suggested  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 47.
[0-20] [0 - 20][0 - 47][20-40]
Ident.Authors (with country if any)Title
000016 (2009) Mao Mao An [République populaire de Chine] ; Zui Zou [République populaire de Chine] ; Hui Shen [République populaire de Chine] ; Jun Dong Zhang [République populaire de Chine] ; Yong Bing Cao [République populaire de Chine] ; Yuan Ying Jiang [République populaire de Chine]The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials
000029 (2011) Satoru Shinriki [Japon] ; Hirofumi Jono [Japon] ; Mitsuharu Ueda [Japon] ; Kazutoshi Ota [Japon] ; Tomoko Ota [Japon] ; Takanao Sueyoshi [Japon] ; Yuichi Oike [Japon] ; Mutsuko Ibusuki [Japon] ; Akimitsu Hiraki [Japon] ; Hideki Nakayama [Japon] ; Masanori Shinohara [Japon] ; Yukio Ando [Japon]Interleukin‐6 signalling regulates vascular endothelial growth factor‐C synthesis and lymphangiogenesis in human oral squamous cell carcinoma
000030 (2010) Katja Perdan-Pirkmajer [Slovénie] ; Sonja Praprotnik [Slovénie] ; Matija Tomši [Slovénie]A case of refractory adult-onset Still’s disease successfully controlled with tocilizumab and a review of the literature
000049 (2012) Hubert De Boysson [France] ; Jérome Février [France] ; Amélie Nicolle [France] ; Christophe Auzary [France] ; Loïk Geffray [France]Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence
000066 (2013) Kanae Tani [Japon] ; Risa Takayanagi [Japon] ; Haruko Yokoyama [Japon] ; Yasuhiko Yamada [Japon]Theoretical analysis of efficacy of biological agent for rheumatoid arthritis based on target molecular binding occupancy
000069 (2016) Nozomu Yanaihara [Japon] ; Yukihiro Hirata [Japon] ; Noriko Yamaguchi [Japon] ; Yukiko Noguchi [Japon] ; Misato Saito [Japon] ; Chie Nagata [Japon] ; Satoshi Takakura [Japon] ; Kyosuke Yamada [Japon] ; Aikou Okamoto [Japon]Antitumor effects of interleukin‐6 (IL‐6)/interleukin‐6 receptor (IL‐6R) signaling pathway inhibition in clear cell carcinoma of the ovary
000075 (2011) J. D. Alves [Portugal] ; A. Marinho [Portugal] ; M. J. Serra [Portugal]Tocilizumab: is there life beyond anti‐TNF blockade?
000088 (2011) Emily Beth Devine [États-Unis] ; Rafael Alfonso-Cristancho [États-Unis] ; Sean D. Sullivan [États-Unis]Effectiveness of Biologic Therapies for Rheumatoid Arthritis: An Indirect Comparisons Approach
000089 (2013) Alfredo Adán [Espagne] ; Marina Mesquida [Espagne] ; Victor Llorenç [Espagne] ; Gerard Espinosa [Espagne] ; Blanca Molins [Espagne] ; Maria V. Hernández [Espagne] ; Laura Pelegrín [Espagne]Tocilizumab treatment for refractory uveitis-related cystoid macular edema
000149 (2010) J. Wollenhaupt [Allemagne] ; K. Krüger [Allemagne]Nicht-TNF-Biologika in der Therapiestrategie bei rheumatoider Arthritis
000161 (2013) I. Kötter [Allemagne] ; J. C. Henes [Allemagne]Etablierte Medikamente
000169 (2015) Yanli Zhuang [États-Unis] ; Dick E. De Vries [Pays-Bas] ; Zhenhua Xu [États-Unis] ; Stanley J. Marciniak Jr. [États-Unis] ; Dion Chen [États-Unis] ; Francisco Leon [États-Unis] ; Hugh M. Davis [États-Unis] ; Honghui Zhou [États-Unis]Evaluation of disease‐mediated therapeutic protein–drug interactions between an anti–interleukin‐6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach
000189 (2013) Diogo Mendes [Portugal] ; Carlos Alves [Portugal] ; Francisco Batel Marques [Portugal]Safety of biologics approved for treating rheumatoid arthritis: analysis of spontaneous reports of adverse events
000222 (2008) M. Aringer [Allemagne] ; E. Feierl [Autriche] ; J. Smolen [Autriche]Zytokinblockade – eine vielversprechende Therapieoption bei SLE
000241 (2010) Tamotsu Kamishima [Japon] ; Kazuhide Tanimura [Japon] ; Yuko Aoki [Japon] ; Naoki Kosaka [Japon] ; Masato Shimizu [Japon] ; Megumi Matsuhashi [Japon] ; Jun Fukae [Japon] ; Yujiro Kon [Royaume-Uni] ; Satoshi Terae [Japon] ; Hiroki Shirato [Japon]Simplified approach to MR image quantification of the rheumatoid wrist: a pilot study
000303 (2013) Verena Wieser [Autriche] ; Alexander R. Moschen [Autriche] ; Herbert Tilg [Autriche]Inflammation, Cytokines and Insulin Resistance: A Clinical Perspective
000304 (2013) Tomokazu Nagao ; Reina Kusunoki ; Chiaki Iwamura ; Shigeto Kobayashi ; Wako Yumura ; Yosuke Kameoka [Japon] ; Toshinori Nakayama ; Kazuo Suzuki [Japon]Correlation of interleukin‐6 and monocyte chemotactic protein‐1 concentrations with crescent formation and myeloperoxidase‐specific anti‐neutrophil cytoplasmic antibody titer in SCG/Kj mice by treatment with anti‐interleukin‐6 receptor antibody or mizoribine
000331 (2012) Yoshikuni Mimata [Japon] ; Akihisa Kamataki ; Shinya Oikawa [Japon] ; Kenya Murakami [Japon] ; Miwa Uzuki ; Tadashi Shimamura [Japon] ; Takashi SawaiInterleukin‐6 upregulates expression of ADAMTS‐4 in fibroblast‐like synoviocytes from patients with rheumatoid arthritis
000461 (2011) Alberto Migliore [Italie, Espagne] ; Emanuele Bizzi [Italie] ; Serena Broccoli [Italie] ; Bruno Laganà [Italie]Indirect comparison of etanercept, infliximab, and adalimumab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator
000520 (2013) C. Carnovale [Italie] ; V. Perrone [Italie] ; C. Borsadoli [Italie] ; A. Mambrini [Italie] ; A. Speziali [Italie] ; G. Froldi [Italie] ; S. Antoniazzi [Italie] ; L. Magistro [Italie] ; E. Clementi [Italie] ; S. Radice [Italie]A case of urinary incontinence by hydroxychloroquine in a geriatric patient
000545 (2011) H. Tadaki [Japon] ; H. Saitsu [Japon] ; H. Kanegane [Japon] ; N. Miyake [Japon] ; T. Imagawa [Japon] ; M. Kikuchi [Japon] ; R. Hara [Japon] ; U. Kaneko [Japon] ; T. Kishi [Japon] ; T. Miyamae [Japon] ; A. Nishimura [Japon] ; H. Doi [Japon] ; Y. Tsurusaki [Japon] ; H. Sakai [Japon] ; S. Yokota [Japon] ; N. Matsumoto [Japon]Exonic deletion of CASP10 in a patient presenting with systemic juvenile idiopathic arthritis, but not with autoimmune lymphoproliferative syndrome type IIa

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Istex/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i -k "suggest" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i  \
                -Sk "suggest" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Istex
   |étape=   Curation
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    suggest
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021